RecruitingNCT07677254

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform


Sponsor

Novartis Pharmaceuticals

Enrollment

17,111 participants

Start Date

Jun 30, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 115 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with prostatic neoplasms, castration-resistant. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 115 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Novartis

East Hanover, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07677254


Related Trials